Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-22
    E.g., 2018-02-22

Archive Search


254539 items
2:56 PM, Feb 22, 2018  |  BioCentury | Finance

Belgian Insights

Belgium has provided Europe with a host of pioneering biotechs, led by CEOs who have demonstrated resilience and stamina in the pursuit of homegrown innovation. The opening evening session on May 14 at Bio€quity Europe...
2:56 PM, Feb 22, 2018  |  BC Extra | Clinical News

Apellis reports 18-month data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....
2:44 PM, Feb 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Mesoblast's MSCs meet in Phase III for acute GvHD

Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said remestemcel-L (MSC-100-IV) met the primary endpoint in a Phase III trial to treat steroid-refractory acute graft-versus-host disease (GvHD). The company said full data from the trial, which are expected next...
2:44 PM, Feb 22, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Aimmune's peanut allergy therapy meets in Phase III

Aimmune Therapeutics Inc. (NASDAQ:AIMT) said AR101 met the primary endpoint in the Phase III PALISADE trial to treat peanut allergy, but also reported that a greater proportion of patients in the active arm discontinued treatment...
1:59 PM, Feb 22, 2018  |  BC Extra | Politics & Policy

Court sides with FDA in Sensipar exclusivity case

A federal court sided with FDA in a lawsuit in which Amgen Inc. (NASDAQ:AMGN) alleged that the agency had applied standards inconsistently when it denied pediatric exclusivity to Amgen's Sensipar cinacalcet, despite granting the same...
1:22 PM, Feb 22, 2018  |  BC Extra | Clinical News

Novo's oral GLP-1 analog meets in first Phase IIIa for Type II diabetes

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said oral semaglutide met the primary endpoint in the Phase IIIa PIONEER 1 trial to treat Type II diabetes. The candidate is on track to be the first approved oral...
1:12 PM, Feb 22, 2018  |  BC Innovations | Finance

Bigger BRAIN Initiative

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is preparing to push projects in three areas past the pilot phase with $169 million in new NIH grants announced in 4Q17. The aim is to...
12:27 PM, Feb 22, 2018  |  BC Innovations | Emerging Company Profile

Informing infection

Inflammatix Inc. measures gene expression patterns in host cells to diagnose and inform treatment decisions for acute infections and sepsis faster than marketed tests. By following the host response, not the pathogen, the company can...
12:03 PM, Feb 22, 2018  |  BC Extra | Financial News

Ascendis, Aimmune price upsized follow-ons

Endocrinology company Ascendis Pharma A/S (NASDAQ:ASND) and allergy play Aimmune Therapeutics Inc. (NASDAQ:AIMT) raised a total of $401 million late Wednesday in bumped-up follow-ons. Ascendis raised $225 million through the sale of 3.9 million ADSs at...
11:31 AM, Feb 22, 2018  |  BC Extra | Company News

Positive CHMP vote likely for Clovis' PARP inhibitor

Clovis Oncology Inc. (NASDAQ:CLVS) rose $4.95 to $59.88 on Thursday after it said EMA's CHMP communicated a "positive trend vote" for an MAA for rucaparib (CO-338) to treat platinum-sensitive, BRCA-mutant advanced ovarian cancer. Clovis expects...